Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-CEA BiTE Monoclonal Antibody MEDI-565, Human

Known as: MEDI-565 
 
National Institutes of Health

Related topics

Related topics

2 relations
Anti-CEA BiTE Monoclonal Antibody AMG211MT111

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
INTRODUCTION MEDI-565, a bispecific, single-chain antibody targeting human carcinoembryonic antigen on tumor cells and the CD3… Expand
2016
2016
Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas.
320 Background: MEDI-565, a bispecific single-chain antibody, targets human CEA on tumor cells and the CD3 epsilon subunit of the… Expand
2015
2015
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
TPS3097 Background: The bispecific CD19-directed CD3 T-cell engager (BiTE(R)) blinatumomab was recently approved by FDA as single… Expand
Highly Cited
2014
Highly Cited
2014
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Individual or combinations of somatic mutations found in genes from colorectal cancers can redirect the effects of chemotherapy… Expand
2012
2012
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in development for the treatment of patients with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Abstract 3524: A novel approach to targeting mutated colorectal adenocarcinomas with T cell-engaging CEA/CD3-bispecific BiTE investigational antibody MEDI-565
Colorectal cancer (CRC) cells can harbor somatic mutations with strong impact on cancer cell signaling that limit the… Expand
Highly Cited
2010
Highly Cited
2010
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
Background:Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 3
  • figure 4
2010
2010
Abstract 5338: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody
Carcinoembryonic antigen (CEA; CD66e, CEACAM5) is a well-characterized tumor-associated antigen that is frequently and uniformly… Expand
2010
2010
Abstract 2584: The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope present in the full-length but not a short splice variant of CEA
MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bi-specific T-cell engager) class that transiently… Expand
2010
2010
Abstract 5625:In vitroandin vivopharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas
MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bispecific T cell engager) class that transiently links… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE